Increased urinary cystatin C level is associated with interstitial fibrosis and tubular atrophy in kidney allograft recipients

Mendes, Maria de Fátima Castro; Salgado, João Victor; Lima, José de Ribamar Medeiros; Ferreira, Teresa Cristina Alves; Silva, Gyl Eanes Barros; Filho, Natalino Salgado

doi:10.1016/j.clinbiochem.2015.02.008

Cited by 4 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[22] The elevated levels of urinary CYSC are associated with interstitial fibrosis and tubular atrophy in renal transplant recipients, and may become a useful tool for monitoring kidney allografts. [23] …”

Section: Cystatin Cmentioning

confidence: 99%

Urine biomarkers in renal allograft

Wang

Lin

Yuan

et al. 2016

Journal of Translational Internal Medicine

View full text Add to dashboard Cite

There is a high risk for the survival of patients with an end-stage renal disease for kidney transplantation. To avoid rejection by strict medication adherence is of utmost importance to avoid the failure of a kidney transplant. It is imperative to develop non-invasive biomarkers to assess immunity risk, and to ultimately provide guidance for therapeutic decision-making following kidney transplantation. Urine biomarkers may represent the promising non-invasive tools that will help in predicting risk or success rates of kidney transplantations. Furthermore, composite urinary biomarkers or urinary biomarker panel array might be critical in improving the sensitivity and specificity in reflecting various risks of kidney failure during transplantation. This review primarily focuses on the role of such biomarkers in predicting chronic kidney disease (CKD) progression and/or cardiovascular disease (CVD) risk in renal allograft.

show abstract

Section: Cystatin Cmentioning

confidence: 99%